Anticipation for GB-0895 Phase 1b data at ERS Congress drives GENB gain
Anticipation for GB-0895 Phase 1b data at ERS Congress drives GENB 10.67% gain
- Q2 earnings (Aug 6) highlighted upcoming Sept 8 ERS presentation of GB-0895 COPD data.
- Phase 1b readout covers safety, PK/PD for anti-TSLP mAb in COPD/asthma program.
- Stock hit new all-time highs with elevated volume and short covering.
- Post-IPO lock-up expiration around Aug 26 added technical momentum.
- Strong cash position ($457M post-IPO) supports AI-driven pipeline progress.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.